PCSK9 inhibitor monoclonal antibody
This page covers all PCSK9 inhibitor monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PCSK9.
Targets
Phase 3 pipeline (1)
- Evolocumab AMD · Amgen · Cardiovascular
Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood.
Patent intelligence
- pcsk9 inhibitor monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates